Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Gilberto de Castro et al.|The Lancet|2019Cited by 3.3k
FGFR a promising druggable target in cancer: Molecular biology and new drugsRut Porta, Christian Rolfo, Roberto Borea et al.|Critical Reviews in Oncology/Hematology|2017Cited by 203
Immunotherapy in NSCLC: A Promising and Revolutionary WeaponChristian Rolfo, Mauricio Mahave, Christian Caglevic et al.|Advances in experimental medicine and biology|2017Cited by 143